[go: up one dir, main page]

ZA972199B - Novel bridged cyclic amino acids as pharmaceutical agents. - Google Patents

Novel bridged cyclic amino acids as pharmaceutical agents.

Info

Publication number
ZA972199B
ZA972199B ZA9702199A ZA972199A ZA972199B ZA 972199 B ZA972199 B ZA 972199B ZA 9702199 A ZA9702199 A ZA 9702199A ZA 972199 A ZA972199 A ZA 972199A ZA 972199 B ZA972199 B ZA 972199B
Authority
ZA
South Africa
Prior art keywords
amino acids
pct
cyclic amino
pharmaceutical agents
bridged cyclic
Prior art date
Application number
ZA9702199A
Other languages
English (en)
Inventor
David Christopher Horwell
Clare O Keen
Giles S Ratcliffe
Justin S Bryans
Andrew I Morrell
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ZA972199B publication Critical patent/ZA972199B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/12Antiepileptics; Anticonvulsants for grand-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/36Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/36Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/46Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing nine carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA9702199A 1996-03-14 1997-03-13 Novel bridged cyclic amino acids as pharmaceutical agents. ZA972199B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1343396P 1996-03-14 1996-03-14

Publications (1)

Publication Number Publication Date
ZA972199B true ZA972199B (en) 1997-09-17

Family

ID=21759944

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9702199A ZA972199B (en) 1996-03-14 1997-03-13 Novel bridged cyclic amino acids as pharmaceutical agents.

Country Status (18)

Country Link
US (1) US6020370A (xx)
EP (1) EP0888285B1 (xx)
JP (1) JP2000506862A (xx)
KR (1) KR100487032B1 (xx)
AT (1) ATE210629T1 (xx)
AU (1) AU731279B2 (xx)
BR (1) BR9708180A (xx)
CZ (1) CZ287598A3 (xx)
DE (1) DE69709070T2 (xx)
EA (1) EA001214B1 (xx)
ES (1) ES2169848T3 (xx)
IL (1) IL125364A0 (xx)
NO (1) NO984204D0 (xx)
NZ (1) NZ331142A (xx)
PL (1) PL185990B1 (xx)
SK (1) SK282848B6 (xx)
WO (1) WO1997033859A1 (xx)
ZA (1) ZA972199B (xx)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU714980B2 (en) 1996-07-24 2000-01-13 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
DE69814420T2 (de) * 1997-09-18 2003-11-27 Warner-Lambert Co. Llc, Morris Plains Stereoselektive verfahren zur herstellung von gabapentinanalogen
DE19751062A1 (de) 1997-11-18 1999-07-08 Univ Ludwigs Albert An 4-Stellung substituierte 2-Pyrrolidinon-Derivate zur Verringerung des extrazellulären Glutamat-Spiegels
US6984659B2 (en) 1997-11-18 2006-01-10 Klinikum Der Albert-Ludwigs Universitaet 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level
PT1047678E (pt) * 1997-12-16 2004-12-31 Warner Lambert Co Derivados do 1-aminometil-cicloalcano substituido em 1 (=analogos da gabapentina) sua preparacao e sua utilizacao no tratamento de disturbios neurologicos
NZ506793A (en) 1998-05-26 2003-03-28 Warner Lambert Co Conformationally constrained amino acid compounds and their use for treating epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain and neuropathological disorders
JP2002520300A (ja) * 1998-07-09 2002-07-09 ワーナー−ランバート・カンパニー Gaba類縁体及び抗ウイルス剤を含んでなる帯状ヘルペスを治療するための医薬組成物
NZ517044A (en) 1999-07-22 2004-02-27 Univ Rochester Gamma-aminobutyric acid analogues, e.g. gabapentin and pregabalin, to treat symptoms of hormonal variation, including hot flushes, nausea, emesis and fever
AU2001247762A1 (en) * 2000-03-28 2001-10-08 Delorenzo, Robert, J Inhibition of a novel calcium injury current that forms in neurons during injury prevents neuronal cell death
CN1279900C (zh) * 2000-06-26 2006-10-18 沃尼尔·朗伯公司 用于睡眠障碍的加巴喷丁类似物
US6900192B2 (en) * 2000-10-06 2005-05-31 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
AU2002211863A1 (en) 2000-10-06 2002-04-15 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
NZ528151A (en) * 2001-04-19 2005-04-29 Warner Lambert Co Fused bicyclic or tricyclic amino acids
GB2374595A (en) * 2001-04-19 2002-10-23 Warner Lambert Co Fused bicyclic or tricyclic amino acids
AU2002345638A1 (en) * 2001-06-11 2002-12-23 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) * 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CN1533270A (zh) 2001-06-11 2004-09-29 ʲŵ�������޹�˾ 具有降低毒性的gaba类似物前药的口服给药剂型
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
WO2003077902A1 (en) 2002-02-19 2003-09-25 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
WO2003080588A1 (en) 2002-03-20 2003-10-02 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
CA2484891A1 (en) * 2002-05-07 2003-11-20 A & D Bioscience, Inc. Conjugates comprising central nervous system active drug
US7183259B2 (en) * 2002-05-17 2007-02-27 Xenoport Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
US7060727B2 (en) 2002-12-11 2006-06-13 Xenoport, Inc. Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
WO2004053192A1 (en) * 2002-12-11 2004-06-24 Xenoport, Inc. Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
CA2679030A1 (en) 2002-12-13 2004-07-01 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary track symptoms
CA2520468A1 (en) * 2003-03-31 2004-10-21 Xenoport, Inc. Treating or preventing hot flashes using prodrugs of gaba analogs
KR20060119971A (ko) 2003-09-11 2006-11-24 제노포트 인코포레이티드 Gaba 유사체의 전구약물을 이용한 요실금의 치료및/또는 예방
KR100828218B1 (ko) 2003-09-12 2008-05-07 화이자 인코포레이티드 알파-2-델타 리간드 및 세로토닌/노르아드레날린 재흡수 억제제를 포함하는 조합물
AU2004274002B2 (en) * 2003-09-17 2011-04-28 Arbor Pharmaceuticals, Llc Treating or preventing restless legs syndrome using prodrugs of GABA analogs
DK1677767T3 (da) * 2003-10-14 2011-10-24 Xenoport Inc Krystallinsk form af gamma-aminobutyrsyre-analog
ES2515092T3 (es) 2003-12-11 2014-10-29 Sunovion Pharmaceuticals Inc. Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión
AU2005301970B2 (en) 2004-11-04 2011-06-02 Arbor Pharmaceuticals, Llc Gabapentin prodrug sustained release oral dosage forms
AU2006325820B2 (en) * 2005-12-12 2013-02-14 Allaccem, Inc. Methods and systems for preparing antimicrobial films and coatings
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
EP2101752A1 (en) * 2006-12-08 2009-09-23 Xenoport, Inc. Use of prodrugs of gaba analogs for treating diseases
HRP20110634T1 (hr) 2006-12-22 2011-10-31 Recordati Ireland Limited KOMBINIRANA TERAPIJA LIGANADA α<SUB>2</SUB>δ I NSAID ZA POREMEĆAJE DONJEG URINARNOG TRAKTA
AU2008218275B2 (en) 2007-02-21 2013-06-20 Allaccem, Incorporated Bridged polycyclic compound based compositions for the inhibition and amelioration of disease
TW200908957A (en) * 2007-06-15 2009-03-01 Xenoport Inc Use of prodrugs of GABA analogs, antispasticity agents, and prodrugs of GABAB receptor agonists for treating spasticity
US8188068B2 (en) * 2007-08-10 2012-05-29 Allaccem, Inc. Bridged polycyclic compound based compositions for coating oral surfaces in pets
US8153618B2 (en) * 2007-08-10 2012-04-10 Allaccem, Inc. Bridged polycyclic compound based compositions for topical applications for pets
US8153617B2 (en) * 2007-08-10 2012-04-10 Allaccem, Inc. Bridged polycyclic compound based compositions for coating oral surfaces in humans
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2009061934A1 (en) * 2007-11-06 2009-05-14 Xenoport, Inc. Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain
EP2250148B1 (en) 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
JP5291123B2 (ja) * 2008-01-25 2013-09-18 ゼノポート,インコーポレイティド (3s)−アミノメチル−5−ヘキサン酸プロドラッグの結晶形態及びその使用
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
CA2732984A1 (en) * 2008-08-07 2010-02-11 Kyorin Pharmaceutical Co., Ltd. Process for production of bicyclo[2.2.2]octylamine derivative
CN102216257B (zh) 2008-10-08 2015-11-25 凯飞药业公司 Gaba偶联物及其使用方法
WO2010084798A1 (ja) * 2009-01-21 2010-07-29 第一三共株式会社 3環性化合物
US20110130454A1 (en) * 2009-11-24 2011-06-02 Xenoport, Inc. Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof
US20110124705A1 (en) * 2009-11-24 2011-05-26 Xenoport, Inc. Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
HUE047629T2 (hu) 2013-01-28 2020-05-28 Lopez Hector L Eljárások ß-alanin tolerancia, farmakodinamika és hatékonyság javítására és azok alkalmazása
EP4227293A3 (en) 2018-05-14 2023-10-04 Xgene Pharmaceutical Inc Crystalline forms of 1-(acyloxy)-alkyl carbamate drug conjugates of naproxen and pregabalin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3743742A (en) * 1969-06-17 1973-07-03 Merck & Co Inc Producing anti-fibrinolytic activity with aminobicycloacetic acid derivatives
US3641129A (en) * 1969-06-17 1972-02-08 Merck & Co Inc Antifibrinolytic compounds
YU36150B (en) * 1974-11-22 1982-02-25 Pliva Zagreb Process for preparing alpha-amino-1-adamantyl acetic acid
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2543821C2 (de) * 1974-12-21 1984-10-18 Gödecke AG, 1000 Berlin Bestimmte Salze und Ester von 1-Aminomethyl-1-cycloalkanessigsäuren und diese Verbindungen enthaltende Arzneimittel

Also Published As

Publication number Publication date
NZ331142A (en) 2001-04-27
KR19990087755A (ko) 1999-12-27
IL125364A0 (en) 1999-03-12
EA001214B1 (ru) 2000-12-25
EP0888285B1 (en) 2001-12-12
EP0888285A1 (en) 1999-01-07
JP2000506862A (ja) 2000-06-06
PL185990B1 (pl) 2003-09-30
NO984204L (no) 1998-09-11
US6020370A (en) 2000-02-01
ES2169848T3 (es) 2002-07-16
DE69709070T2 (de) 2002-06-20
ATE210629T1 (de) 2001-12-15
KR100487032B1 (ko) 2005-12-21
BR9708180A (pt) 1999-07-27
AU731279B2 (en) 2001-03-29
CZ287598A3 (cs) 1999-02-17
SK124898A3 (en) 1999-02-11
NO984204D0 (no) 1998-09-11
SK282848B6 (sk) 2002-12-03
DE69709070D1 (de) 2002-01-24
EA199800797A1 (ru) 1999-04-29
AU2127197A (en) 1997-10-01
PL328800A1 (en) 1999-02-15
WO1997033859A1 (en) 1997-09-18

Similar Documents

Publication Publication Date Title
ZA972200B (en) Novel bridged cyclic amino acids as pharmaceutical agents.
ZA972199B (en) Novel bridged cyclic amino acids as pharmaceutical agents.
ZA97991B (en) Novel cyclic amino acids as pharmaceutical agents.
HRP970560B1 (en) Substituted gamma aminobutyric acids as pharmaceutical agents
TW200505824A (en) Bicyclic amino acids as pharmaceutical agents
AU4673300A (en) Amino heterocycles useful as pharmaceutical agents
CA2245647A1 (en) Novel bridged cyclic amino acids as pharmaceutical agents